New Pure Play Novartis Vows To Up Its Game – With Help From In-House Challenger Ronny Gal
‘US First’ Policy To Boost Growth
Executive Summary
Having finally confirmed the Sandoz spin-off, Novartis will become a 'pure play' pharma company and focus on picking bigger blockbuster winners from both internal and external pipelines. CEO Vas Narasimhan talked details at an investor day in Basel.
You may also be interested in...
Novartis Has A New Goal: $2bn Peak Sales Per Product
The company said during its R&D day that it has culled its pipeline to 103 clinical stage assets, choosing to focus on drugs that could be big blockbusters.
BioAsia 2023: Leaders from Novartis, Apple Talk Innovation, Tech, Data Privacy
BioAsia 2023 was a melting pot of ideas with Novartis's CEO and a senior executive from Apple, among others, discussing a range of topics including the potential of novel therapies and platforms such as siRNA and radioligand and also where things were headed as the union of technology and biotech drives new insights into biology and promises to help reimagine healthcare.
Novartis On Its ‘US First’ Commercial Plan
US Innovative Medicines president Victor Bulto talked to Scrip about why the company is pivoting to a commercial strategy that prioritizes the US and what that means for developing and selling drugs.